SCHEMBL5165151

SCHEMBL5165151

CCNc1nc(C)c(C(=C=O)CN(C)C)s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.40
ALDH1A1 P00352 6/20 0.39
NPC1 O15118 6/20 0.39
RAB9A P51151 3/20 0.36
HPGD P15428 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
KMT2A Q03164 2/20 0.36
CRHR1 P34998 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.34
MAPK1 P28482 1/20 0.34
BRCA1 P38398 1/20 0.34
HTT P42858 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6158103 0.87 NPC1 (0.40) MAPK14ALDH1A1NPC1RAB9ARXFP1
SCHEMBL5159025 0.86 L3MBTL1 (0.45) ALDH1A1NPC1RAB9AHPGDRXFP1
SCHEMBL5164299 0.83 ALDH1A1 (0.61) ALDH1A1NPC1RAB9AKMT2ACRHR1
SCHEMBL5159455 0.82 ALDH1A1 (0.36) ALDH1A1NPC1RAB9AHPGDRXFP1
SCHEMBL5164166 0.82 RAB9A (0.37) ALDH1A1NPC1RAB9AHPGDKMT2A
SCHEMBL5164158 0.81 NPC1 (0.58) ALDH1A1NPC1RAB9AHPGDRXFP1
SCHEMBL5162743 0.80 NPC1 (0.67) ALDH1A1NPC1RAB9AKMT2AMAPT
SCHEMBL5737503 0.79 NPC1 (0.50) ALDH1A1NPC1RAB9AHPGDRXFP1
SCHEMBL5159325 0.78 RAB9A (0.56) ALDH1A1NPC1RAB9AHPGDKMT2A
SCHEMBL5161599 0.77 ALDH1A1 (0.35) ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed
EP-1567522-A1 PYRIMIDINE COMPOUNDS Cyclacel Limited (GB) 2005-08-31 EP disclosed
WO-2005052147-A2 METHOD OF SCREENING FOR A MODULATOR OF CDK4 CYCLACEL LIMITED (GB) 2005-06-09 WO disclosed
EP-1430051-A1 N-(4-(4-METHYLTHIAZOL-5-YL)PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS Cyclacel Limited (GB) 2004-06-23 EP disclosed
WO-2004043953-A1 PYRIMIDINE COMPOUNDS CYCLACEL LIMITED (GB) 2004-05-27 WO disclosed
WO-2003029248-A1 N-(4-(4-METHYLTHIAZOL-5-YL) PYRIMIDIN-2-YL) -N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS CYCLACEL LIMITED (GB) 2003-04-10 WO disclosed
EP-1274705-A1 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2003-01-15 EP disclosed
WO-2001072745-A1 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2001-10-04 WO disclosed